 25378.04    19 July 2017 4:02 PM     Proof 5
6
consortmedical.com 
Stock Code: CSRT
OUR BUSINESS
Strategic Report
GROUP AT  
A GLANCE
SALES PRESENCE IN CHINA, INDIA, 
JAPAN AND NORTH AND SOUTH AMERICA
UK
Cramlington (Aesica API) 1
Newcastle (Aesica Corporate) 2
Nelson (IAC) 3
Milton Keynes (Bespak manufacturing) 4
Hemel Hempstead (Consort HQ) 5
Queenborough (Aesica API/FDM/FDD) 6
Cambridge (Innovation Centre) 7
King’s Lynn (Bespak manufacturing) 8
1
2
3
4
5
6
7
8
GERMANY
Monheim (Aesica FDM) 9
Zwickau (Aesica FDM) 10
9
10
ITALY
Pianezza (Aesica FDM) 11
11
A leading global 
CDMO providing 
advanced delivery 
technologies, 
formulation and 
manufacturing 
solutions for drugs.
DRUG 
DISCOVERY
DRUG 
DEVELOPMENT
API 
MANUFACTURE
DRUG FORMULATION 
DEVELOPMENT
DEVICE FEASIBILITY, 
CONCEPT AND  
INITIAL DESIGN
DEVICE DETAILED 
DESIGN AND 
DEVELOPMENT
DEVICE PILOT,  
CLINICAL AND LOW 
VOLUME PRODUCTION
DEVICE HIGH  
VOLUME COMMERCIAL 
PRODUCTION
FORMULATED PRODUCT 
MANUFACTURE
BESPAK DEVICES BESPAK DEVICES BESPAK DEVICES BESPAK DEVICES
DRUG/DEVICE 
ASSEMBLY 
(FILL/FINISH)
AESICA API AND FINISHED DOSE AESICA API AND FINISHED DOSE AESICA API AND FINISHED DOSE AESICA AND BESPAK CUSTOMER CUSTOMER
BESPAK — DEVICES
GROUP
AESICA — DRUGS
• A global market leader in the 
development and manufacture 
of drug delivery devices, serving 
pharmaceutical companies 
with inhaler, auto-injector, 
nasal and ocular technologies 
and development and 
manufacturing services
• Benchmark capabilities in the 
manufacture of more than 
500 million devices per year in 
regulated markets
• One of only a handful of 
operators globally who have 
the know-how and expertise to 
consistently deliver above Six 
Sigma quality for high volume 
medical components and 
devices 
 > The Group’s customers include 
some of the world’s largest 
pharmaceutical companies
 > Significant product invention 
and development resources 
in R&D including a separate 
Innovation team in Cambridge
 > High barriers to entry: highly 
embedded customer 
relationships, intellectual 
property, know-how, regulatory 
approvals, manufacturing 
complexity and economies  
of scale
 > Robust finances: profitable, cash 
generative, low gearing and 
high dividend payout
• A leading pharmaceutical 
CDMO serving 
pharmaceutical 
companies with API and 
finished dose formulation 
development and 
manufacturing services
• The only independent 
CDMO with semi-
continuous manufacturing 
capabilities
SALES PRESENCE IN CHINA, INDIA, 
JAPAN AND NORTH AND SOUTH AMERICA
DRUG 
DISCOVERY
DRUG 
DEVELOPMENT
API 
MANUFACTURE
DRUG FORMULATION 
DEVELOPMENT
DEVICE FEASIBILITY, 
CONCEPT AND  
INITIAL DESIGN
DEVICE DETAILED 
DESIGN AND 
DEVELOPMENT
DEVICE PILOT,  
CLINICAL AND LOW 
VOLUME PRODUCTION
DEVICE HIGH  
VOLUME COMMERCIAL 
PRODUCTION
FORMULATED PRODUCT 
MANUFACTURE
BESPAK DEVICES BESPAK DEVICES BESPAK DEVICES BESPAK DEVICES
DRUG/DEVICE 
ASSEMBLY 
(FILL/FINISH)
AESICA API AND FINISHED DOSE AESICA API AND FINISHED DOSE AESICA API AND FINISHED DOSE AESICA AND BESPAK CUSTOMER CUSTOMER
WHO WE ARE
• Leading global CDMO, providing 
advanced delivery technologies, 
formulation and manufacturing 
solutions for drugs
• Offering customers a single source 
for drug and device development, 
formulation, manufacturing and 
fill/finish, the Group comprises two 
integrated operating divisions:
2
UK
Cramlington (Aesica API) 1
Newcastle (Aesica Corporate)
Nelson (IAC)
Milton Keynes (Bespak manufacturing)
Hemel Hempstead (Consort HQ)
Queenborough (Aesica API/FDM/FDD)
Cambridge (Innovation Centre)
King’s Lynn (Bespak manufacturing)
9
3
4
5
6
7
8
10
GERMANY
Monheim (Aesica FDM)
Zwickau (Aesica FDM)
ITALY
Pianezza (Aesica FDM) 11 25378.04    19 July 2017 4:02 PM     Proof 5
CONSORT MEDICAL PLC 
Annual Report and Accounts for the year ended 30 April 2017 
7
OUR BUSINESS
Strategic Report
OUR STRATEGY
• Sustained organic revenue  
growth from:
 – Leveraging the Group’s core 
strengths with existing and  
new customers
 – Broadening the Group’s services 
offering to capture adjacent 
markets and territories
 – Deepening the Group’s offering, 
capturing more of the value chain
• Operating leverage 
 – Margin expansion from volume 
growth and ongoing cost efficiency
• Drive innovation 
 – To develop new device and 
formulation technologies
• Enhancement
 – Selective acquisitions of, and 
investments in, companies, 
producers and technologies which 
have the potential to leverage the 
Group’s core competencies in  
drug formulation, manufacturing 
and delivery 
KEY PRODUCTS AND SERVICES
• Development, formulation 
and production of formulated 
pharmaceutical products
• API contract development, 
formulation and contract 
manufacturing services
• Respiratory devices: metered dose 
inhaler valves, dry powder inhalers, 
integrated dose counters, actuators
• Injectables devices: auto-injectors, 
needle-free injectors, bolus  
delivery devices
• Nasal devices: nasal drug  
delivery devices
• Ocular devices: ocular drug  
delivery devices
• Other devices: POC diagnostics 
devices, medical check valves
MARKET POSITION
• A leading global CDMO, providing 
advanced delivery technologies, 
formulation development and 
manufacturing solutions for drugs
• Offering customers a single source 
for drug and device development, 
formulation, manufacturing and fill/
finish – a highly differentiated  
offering compared to Consort 
Medical’s competitors
• A global market leader in inhaled 
drug delivery
• Growing franchise in injectables 
and nasal drug delivery and POC 
diagnostics consumables
• Over 500 million devices 
manufactured annually
• 15 major Bespak device programmes 
in development pipeline
• Firm opportunities in attractive new 
growth market segments
• At the leading edge of innovation – 
growing customer recognition as 
innovator on demand
HIGHLIGHTS
• Consort Medical has continued 
to deliver profitable growth on 
a reported basis with operating 
leverage yielding an 8.3% increase in 
EBIT on 6.2% higher sales 
• Underlying Group EBIT, at constant 
exchange rates, was 4.1% higher on 
2.0% of sales growth
• Bespak grew revenues by 3.3% and 
EBIT by 3.9% delivering a further 10bps 
margin improvement to 21.6%
• Aesica recorded a significant 
improvement in operational 
performance with EBIT increasing 
by 17.7% and a further 60bps 
improvement in EBIT margin to 8.0%
• Adjusted basic EPS 13.1% higher than 
FY2016 at 65.1p 
• Final proposed dividend increased 
5.2% to 13.21p, reflecting the good 
financial performance and the 
Board’s confidence in the Group’s 
prospects
• Net debt reduced to £92.6m (FY2016: 
£97.0m) with good cash generation 
following further investments in the 
business. Gearing (Net debt: EBITDA) 
reduced to 1.7x 
• Landmark deal for Bespak with the 
first full development agreement 
for Syrina
®
 / Vapoursoft
®
 device 
application with a leading global 
biopharmaceutical company 
• Successfully launched second Bespak 
injectable device with the UCB 
Cimzia
®
 AutoClicks
®
 pre-filled pen in 
the UK and other European markets
• Launched AstraZeneca’s Bevespi 
Aerosphere
®
 in the US. Bespak 
awarded significant new multi-year 
agreement for the scale-up and 
supply of its proprietary pMDI valves 
and actuators
• On course for double-digit operating 
margins at Aesica including contract 
extensions with one of Aesica’s 
largest customers and additional new 
contract wins
• Aesica now routinely supplying 
commercial product using the first 
semi-continuous processing line 
and technology installed at the 
Queenborough site. Discussions 
underway with a number of pharma 
customers to use this technology
• Aesica is an early provider in 
serialisation services that is a growing 
requirement for pharma clients
• Successful commercial unveiling of 
Syrina
®
 AR 2.25 compact auto-injector
DRUG 
DISCOVERY
DRUG 
DEVELOPMENT
API 
MANUFACTURE
DRUG FORMULATION 
DEVELOPMENT
DEVICE FEASIBILITY, 
CONCEPT AND  
INITIAL DESIGN
DEVICE DETAILED 
DESIGN AND 
DEVELOPMENT
DEVICE PILOT,  
CLINICAL AND LOW 
VOLUME PRODUCTION
DEVICE HIGH  
VOLUME COMMERCIAL 
PRODUCTION
FORMULATED PRODUCT 
MANUFACTURE
BESPAK DEVICES BESPAK DEVICES BESPAK DEVICES BESPAK DEVICES
DRUG/DEVICE 
ASSEMBLY 
(FILL/FINISH)
AESICA API AND FINISHED DOSE AESICA API AND FINISHED DOSE AESICA API AND FINISHED DOSE AESICA AND BESPAK CUSTOMER CUSTOMER
